Diagnostic Methods for Low Grade (More Favorable) Malignant Lymphomas

Presented by

Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics

About this talk

Join us as Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics, presents part 2 of 3 in this series on malignant lymphomas. Low grade lymphomas are slowly progressive neoplasms most typically arising in older patients. They are usually highly sensitive to conventional modes of therapy but can progress into aggressive lethal forms. Usually presenting in an advanced stage, these diseases are difficult to totally eradicate. For the pathologist the critical distinction between lymphoma and benign immune reaction can be difficult, requiring the application of special studies, in particular immunohistochemistry and genetic clonal determination. Case examples representing the commonest differential diagnostic challenges are illustrated.
Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (63)
Subscribers (8351)
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.